Serina Therapeutics (SER) Net Income towards Common Stockholders (2018 - 2025)
Historic Net Income towards Common Stockholders for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to -$6.4 million.
- Serina Therapeutics' Net Income towards Common Stockholders fell 2008.26% to -$6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.4 million, marking a year-over-year decrease of 9589.72%. This contributed to the annual value of -$17.6 million for FY2024, which is 37664.77% down from last year.
- Per Serina Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$6.4 million for Q3 2025, which was down 2008.26% from -$5.6 million recorded in Q2 2025.
- Serina Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $65000.0 during Q4 2023, with a 5-year trough of -$6.4 million in Q3 2025.
- In the last 5 years, Serina Therapeutics' Net Income towards Common Stockholders had a median value of -$2.7 million in 2022 and averaged -$3.1 million.
- As far as peak fluctuations go, Serina Therapeutics' Net Income towards Common Stockholders skyrocketed by 10235.51% in 2023, and later plummeted by 866307.69% in 2024.
- Quarter analysis of 5 years shows Serina Therapeutics' Net Income towards Common Stockholders stood at -$103000.0 in 2021, then tumbled by 2579.61% to -$2.8 million in 2022, then soared by 102.36% to $65000.0 in 2023, then crashed by 8663.08% to -$5.6 million in 2024, then dropped by 14.95% to -$6.4 million in 2025.
- Its last three reported values are -$6.4 million in Q3 2025, -$5.6 million for Q2 2025, and -$5.9 million during Q1 2025.